Cite
Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Cell Transplantation
MLA
Kunter, Ghada M., et al. “Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Cell Transplantation.” Biology of Blood & Marrow Transplantation, vol. 19, no. s2, Feb. 2013, p. S296. EBSCOhost, https://doi.org/10.1016/j.bbmt.2012.11.430.
APA
Kunter, G. M., Perkins, J., Nishihori, T., Locke, F., Field, T., Pidala, J., Perez, L., Kharfan-Dabaja, M., Anasetti, C., & Fernandez, H. (2013). Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood & Marrow Transplantation, 19(s2), S296. https://doi.org/10.1016/j.bbmt.2012.11.430
Chicago
Kunter, Ghada M., Janelle Perkins, Taiga Nishihori, Frederick Locke, Teresa Field, Joseph Pidala, Lia Perez, Mohamed Kharfan-Dabaja, Claudio Anasetti, and Hugo Fernandez. 2013. “Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Cell Transplantation.” Biology of Blood & Marrow Transplantation 19 (s2): S296. doi:10.1016/j.bbmt.2012.11.430.